BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...other opportunities. Additionally, Alicia Hager will join the NK cell therapy company as chief legal officer. Supernus Pharmaceuticals Inc....
...who is retiring. Alexander Ford has resigned as COO of Myriad Genetics Inc. (NASDAQ:MYGN). Virginia Li Maze Therapeutics Expansion Therapeutics Nkarta Inc. Supernus Pharmaceuticals Inc. Myriad...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...were presented at the American Association for Cancer Research virtual meeting. Supernus acquiring neurology portfolio Supernus Pharmaceuticals Inc....
...cell death 1 Hongjiang Li, Staff Writer Tyvyt, sintilimab (IBI308) Avadel Pharmaceuticals plc Innovent Biologics Inc. Eli Lilly and Co. Chimerix Inc. Supernus Pharmaceuticals Inc. Programmed...
BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

...see “Esperion Enters Crowded LDL-lowering Market” ). Supernus discontinues ADHD candidate after Phase III failure Supernus Pharmaceuticals Inc....
...S. Eaton and Hongjiang Li, Staff Writers Cyramza, ramucirumab (IMC-1121B, LY3009806) Tarceva, erlotinib (R1415, RG115, CP-358,774, OSI-774) AB122 bempedoic acid/ezetimibe Supernus Pharmaceuticals Inc. Moderna...
BioCentury | Aug 2, 2019
Finance

Earnings on deck

...NASDAQ:JAZZ) 8/6 Post $3.57 $3.49 2% Horizon Pharma plc (NASDAQ:HZNP) 8/7 Pre $0.38 $0.48 -21% Supernus Pharmaceuticals Inc....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Molindone (SPN-810) Treat impulsive aggression in patients with ADHD Phase III data 2H19 Supernus Pharmaceuticals Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...NASDAQ:JAZZ) 5/7 Post $3.16 $2.98 6% Myriad Genetics Inc. (NASDAQ:MYGN) 5/7 Post $0.42 $0.31 35% Supernus Pharmaceuticals Inc....
BioCentury | Feb 22, 2019
Finance

Earnings on deck

...plc (NASDAQ:JAZZ) 2/26 Post $3.02 $2.95 2% Mylan N.V. (NASDAQ:MYL) 2/26 Post $1.36 $1.43 -5% Supernus Pharmaceuticals Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...trials 1H19; 4Q19 Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Molindone Aggression in patients with ADHD Phase III data Mid-2019 Supernus Pharmaceuticals Inc....
BioCentury | Jan 4, 2019
Clinical News

Supernus' ADHD candidate meets in Phase III in adolescents

...and by 16.5 points at the 400 mg dose (p=0.0091) vs. 11.4 points for placebo. Supernus...
...endpoint in the Phase III P301 and P303 trials to treat children with ADHD (see "Supernus...
...from the final Phase III trial of SPN-812 -- Study P304 in adolescents with ADHD. Supernus Pharmaceuticals Inc....
BioCentury | Dec 7, 2018
Clinical News

Supernus planning NDA for ADHD candidate following Phase III readouts

...the Phase III P302 and P304 trials, respectively, of SPN-812 to treat adolescents with ADHD. Supernus Pharmaceuticals Inc....
...Milestone: Phase III data (12/2018); Phase III data (1Q19); submit NDA (2H19); Market launch (2H20) Brian Moy SPN-812 Supernus Pharmaceuticals Inc. Attention...
Items per page:
1 - 10 of 112
BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...other opportunities. Additionally, Alicia Hager will join the NK cell therapy company as chief legal officer. Supernus Pharmaceuticals Inc....
...who is retiring. Alexander Ford has resigned as COO of Myriad Genetics Inc. (NASDAQ:MYGN). Virginia Li Maze Therapeutics Expansion Therapeutics Nkarta Inc. Supernus Pharmaceuticals Inc. Myriad...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...were presented at the American Association for Cancer Research virtual meeting. Supernus acquiring neurology portfolio Supernus Pharmaceuticals Inc....
...cell death 1 Hongjiang Li, Staff Writer Tyvyt, sintilimab (IBI308) Avadel Pharmaceuticals plc Innovent Biologics Inc. Eli Lilly and Co. Chimerix Inc. Supernus Pharmaceuticals Inc. Programmed...
BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

...see “Esperion Enters Crowded LDL-lowering Market” ). Supernus discontinues ADHD candidate after Phase III failure Supernus Pharmaceuticals Inc....
...S. Eaton and Hongjiang Li, Staff Writers Cyramza, ramucirumab (IMC-1121B, LY3009806) Tarceva, erlotinib (R1415, RG115, CP-358,774, OSI-774) AB122 bempedoic acid/ezetimibe Supernus Pharmaceuticals Inc. Moderna...
BioCentury | Aug 2, 2019
Finance

Earnings on deck

...NASDAQ:JAZZ) 8/6 Post $3.57 $3.49 2% Horizon Pharma plc (NASDAQ:HZNP) 8/7 Pre $0.38 $0.48 -21% Supernus Pharmaceuticals Inc....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Molindone (SPN-810) Treat impulsive aggression in patients with ADHD Phase III data 2H19 Supernus Pharmaceuticals Inc....
BioCentury | May 3, 2019
Finance

Earnings on deck

...NASDAQ:JAZZ) 5/7 Post $3.16 $2.98 6% Myriad Genetics Inc. (NASDAQ:MYGN) 5/7 Post $0.42 $0.31 35% Supernus Pharmaceuticals Inc....
BioCentury | Feb 22, 2019
Finance

Earnings on deck

...plc (NASDAQ:JAZZ) 2/26 Post $3.02 $2.95 2% Mylan N.V. (NASDAQ:MYL) 2/26 Post $1.36 $1.43 -5% Supernus Pharmaceuticals Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...trials 1H19; 4Q19 Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Molindone Aggression in patients with ADHD Phase III data Mid-2019 Supernus Pharmaceuticals Inc....
BioCentury | Jan 4, 2019
Clinical News

Supernus' ADHD candidate meets in Phase III in adolescents

...and by 16.5 points at the 400 mg dose (p=0.0091) vs. 11.4 points for placebo. Supernus...
...endpoint in the Phase III P301 and P303 trials to treat children with ADHD (see "Supernus...
...from the final Phase III trial of SPN-812 -- Study P304 in adolescents with ADHD. Supernus Pharmaceuticals Inc....
BioCentury | Dec 7, 2018
Clinical News

Supernus planning NDA for ADHD candidate following Phase III readouts

...the Phase III P302 and P304 trials, respectively, of SPN-812 to treat adolescents with ADHD. Supernus Pharmaceuticals Inc....
...Milestone: Phase III data (12/2018); Phase III data (1Q19); submit NDA (2H19); Market launch (2H20) Brian Moy SPN-812 Supernus Pharmaceuticals Inc. Attention...
Items per page:
1 - 10 of 112